Keywords: Biogen Idec, Elan, Tysabri, Multiple sclerosis, MS

Early treatment with Biogen and Elan’s Tysabri reduces MS relapse rates

Article | 19 October 2011

Print This

US biotech firm Biogen Idec (Nasdaq: BIIB) and Ireland-based Elan Corp (NYSE: ELN) have released new data on their co-marketed ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in